Business Context and Reporting Period
This Form 8-K filing by Bioaffinity Technologies, Inc. (BIAF) reports on the results of the 2024 Special Meeting of Stockholders held on December 20, 2024. The Company is incorporated in Delaware and trades on the Nasdaq Capital Market. As of the record date (November 15, 2024), there were 15,584,635 shares of Common Stock issued and outstanding.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Stockholders voted on two proposals at the Special Meeting. Both proposals were approved by the requisite majority.
- Proposal No. 1: Issuance of Shares Upon Exercise of Warrants
- Outcome: Approved.
- Details: Authorizes the issuance of up to 2,724,230 shares of Common Stock upon the exercise of warrants issued to institutional investors and placement agent designees in connection with offerings closed on October 21, 2024. This approval satisfies Nasdaq Listing Rules.
- Vote Breakdown: 6,750,134 For; 213,740 Against; 457,750 Abstentions; 0 Broker Non-Votes.
- Proposal No. 2: Adjournment of the Meeting
- Outcome: Approved (though not utilized).
- Details: Authorized the adjournment of the meeting to solicit further proxies if necessary to approve Proposal No. 1. The filing notes this adjournment was not necessary as Proposal No. 1 was approved.
- Vote Breakdown: 7,024,100 For; 177,685 Against; 219,839 Abstentions; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard disclosure that the voting results are subject to the definitive proxy statement filed on November 22, 2024. No unusual items or contingencies were reported in this specific document.
Key Facts for Investor Verification
- Verify the final share count impact of the 2,724,230 warrant shares once exercised.
- Review the definitive proxy statement (Schedule 14A) filed on November 22, 2024, for detailed terms of the October 21, 2024, registered direct and private placement offerings.
- Confirm the Company's compliance with Nasdaq Listing Rules regarding the warrant issuance following this shareholder approval.